Treatment begins in Ph III karenitecin trial
US cancer drug and supportive care specialist BioNumerik Pharmaceuticals says it has treated the first patient in a Phase III trial of karenitecin (BNP1350), its candidate product for women with advanced ovarian cancer. The firm noted that the compound, a member of the camptothecin class of chemotherapy agents, offers a potential reduction in side effects and may be less susceptible to resistance mechanisms than currently-available therapies.
The Phase III trial, which is being run as a global, randomized, multicenter, open-label assessment, is designed to compare the safety and efficacy of karenitecin with Hycamtin (topotecan; made by GlaxoSmithKline). Women enrolled in the program, all of whom have received prior platinum and taxane-based chemotherapy, will receive one of the two drugs, intravenously for five consecutive days, every three weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze